Wilms tumor
Wilms tumor
Explore linked clinical trials. Standard reference: MONDO:000605843 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT04320888 | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-08 | NCT03618381 | |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT03213652 | |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, astrocytoma (excluding glioblastoma), benign urinary system neoplasm, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, ependymoma, epithelial neoplasm, glioblastoma, glioma, gliosarcoma, hereditary disease, hereditary neoplastic syndrome, immune system disorder, immunoproliferative disorder, kidney cancer, kidney disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, pediatric lymphoma, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-01 | NCT03478462 | |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, desmoplastic small round cell tumor, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, neoplasm, osteosarcoma, sarcoma, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT04616560 | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Stomatognathic Diseases, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, benign urinary system neoplasm, brain disorder, carcinoma, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, malignant endocrine neoplasm, medulloblastoma, mesoblastic nephroma, mixed neoplasm, mouth disorder, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, papillary adenocarcinoma, primitive neuroectodermal tumor, salivary gland cancer, salivary gland disorder, sarcoma, thyroid gland disorder, thyroid tumor, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT02650401 | |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, childhood ependymoma, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-22 | NCT03210714 | |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-21 | NCT03698994 | |
| Biomarkers of Resiliency In Childhood Cancer Surgery | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, childhood malignant neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor, sarcoma, urinary system disorder | Recruiting | Not stated | 2026-09-14 | NCT06674811 | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Carcinoma, Medullary, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, alveolar soft part sarcoma, benign urinary system neoplasm, carcinoma, central nervous system cancer, clear cell sarcoma, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, hepatoblastoma, hepatocellular carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, liver disorder, malignant endocrine neoplasm, medullary thyroid gland carcinoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, osteosarcoma, primitive neuroectodermal tumor, renal cell carcinoma, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-08-28 | NCT02867592 | |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Adnexal Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, benign urinary system neoplasm, carcinoma, colonic disorder, colorectal neoplasm, connective tissue neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibroma, gonadal disorder, hepatoblastoma, hepatocellular carcinoma, hereditary disease, hereditary neoplastic syndrome, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mixed neoplasm, neoplasm, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreatic ductal adenocarcinoma, primitive neuroectodermal tumor, rectal disorder, sarcoma, skin disorder, skin neoplasm, solid pseudopapillary neoplasm of the pancreas, urinary system disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-25 | NCT04851119 | |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-08-25 | NCT04322318 | |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Recruiting | Phase 1 | 2026-08-13 | NCT07172958 | |
| Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, liposarcoma, liver cancer, liver disorder, mesonephric neoplasm, mixed neoplasm, myomatous neoplasm, neoplasm, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder, yolk sac tumor | Recruiting | Phase 1 | 2026-08-06 | NCT04715191 | |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytic sarcoma, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, juvenile xanthogranuloma, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant glioma, malignant histiocytosis, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, non-Langerhans cell histiocytosis, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-24 | NCT03155620 | |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, endocrine system disorder, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, medulloblastoma, melanocytic neoplasm, melanoma, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, osteosarcoma, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-15 | NCT04284774 | |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-01 | NCT04195555 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Peripheral Nerve Sheath Tumors, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, alveolar soft part sarcoma, benign urinary system neoplasm, chordoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06625190 | |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-06-17 | NCT03213704 | |
| Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenoma, benign urinary system neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant mesothelioma, malignant pleural mesothelioma, mesothelial neoplasm, mesothelioma, mixed neoplasm, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-05 | NCT05765084 | |
| Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder | 46 XY differences of sex development, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Denys-Drash syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Abnormalities, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, disorder of sexual differentiation, endocrine system disorder, gonadal disorder, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, neoplasm, urinary system disorder | Not yet recruiting | Not stated | 2026-05-26 | NCT07605884 | |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, epithelial neoplasm, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-19 | NCT04901702 | |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | Adrenocortical Cancer, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, endocrine system disorder, epithelial neoplasm, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, malignant endocrine neoplasm, malignant germ cell tumor, melanocytic neoplasm, melanoma, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, skin neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-05-19 | NCT04897321 | |
| INVESTIGATION OF THE GENETIC ETIOLOGY OF HERNIA SAC DEVELOPMENT IN MALE CHILDREN WITH UNDESCENDED TESTIS AND INGUINAL HERNIA | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hernia, Hernia, Abdominal, Hernia, Inguinal, Inguinal Hernia, Indirect, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Urogenital Abnormalities, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, cryptorchidism, endocrine system disorder, gonadal disorder, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, male reproductive system disorder, mixed neoplasm, neoplasm, testicular disorder, urinary system disorder | Active, not recruiting | Not stated | 2026-05-14 | NCT07586332 | |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, epithelial neoplasm, glioma, head and neck squamous cell carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, medulloblastoma, mixed neoplasm, myomatous neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, nasopharyngeal type undifferentiated carcinoma, neoplasm, neuroblastoma, neuroepithelial neoplasm, otorhinolaryngologic disease, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, squamous cell carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-05-13 | NCT07584499 |